LABELS · 228e1e3f-d207-481f-8e14-9fdcbd0470e9
KEYTRUDA
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2026-07-10
- Captured
- 2026-09-09T23:37:42.544548+00:00
- Current indication reconciliation
- Not reconciled
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) in combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.20 , 2.1 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.20 , 2.1 ) Ovarian Cancer in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens. ( 1.21 , 2.1 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 1.1 Melanoma KEYTRUDA ® is indicated for the treatment of patients with unresectable or metastatic melanoma. KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. 1.2 Non-Small Cell Lung Cancer KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC. KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. 1.3 Malignant Pleural Mesothelioma KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). 1.4 Head and Neck Squamous Cell Cancer KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC). KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. 1.5 Classical Hodgkin Lymphoma KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL). KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. 1.6 Primary Mediastinal Large B-Cell Lymphoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. 1.7 Urothelial Cancer KEYTRUDA, in combination with enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. KEYTRUDA, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. KEYTRUDA, in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. 1.8 Microsatellite Instability-High or Mismatch Repair Deficient Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration (2.1) ] . 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.10 Gastric Cancer KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.11 Esophageal Cancer KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.12 Cervical Cancer KEYTRUDA, in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ]. KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.13 Hepatocellular Carcinoma KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. 1.14 Biliary Tract Cancer KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). 1.15 Merkel Cell Carcinoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). 1.16 Renal Cell Carcinoma KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC. KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions [see Clinical Studies (14.16) ] . KEYTRUDA, in combination with belzutifan, is indicated for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. 1.17 Endometrial Carcinoma KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] . KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] . 1.18 Tumor Mutational Burden-High Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.18) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. 1.19 Cutaneous Squamous Cell Carcinoma KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation. 1.20 Triple-Negative Breast Cancer KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYTRUDA, in combination with sacituzumab govitecan-hziy, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.21 Ovarian Cancer KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , and who have received one or two prior systemic treatment regimens.
Full extracted label fields
- application numbers
- BLA125514
- boxed warning exact
- brand names
- KEYTRUDA
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287
- generic names
- PEMBROLIZUMAB
- id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- indications and usage exact
- 1 INDICATIONS AND USAGE KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) in combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.20 , 2.1 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.20 , 2.1 ) Ovarian Cancer in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens. ( 1.21 , 2.1 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 1.1 Melanoma KEYTRUDA ® is indicated for the treatment of patients with unresectable or metastatic melanoma. KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. 1.2 Non-Small Cell Lung Cancer KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC. KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. 1.3 Malignant Pleural Mesothelioma KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). 1.4 Head and Neck Squamous Cell Cancer KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC). KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. 1.5 Classical Hodgkin Lymphoma KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL). KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. 1.6 Primary Mediastinal Large B-Cell Lymphoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. 1.7 Urothelial Cancer KEYTRUDA, in combination with enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. KEYTRUDA, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. KEYTRUDA, in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. 1.8 Microsatellite Instability-High or Mismatch Repair Deficient Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration (2.1) ] . 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.10 Gastric Cancer KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.11 Esophageal Cancer KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.12 Cervical Cancer KEYTRUDA, in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ]. KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.13 Hepatocellular Carcinoma KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. 1.14 Biliary Tract Cancer KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). 1.15 Merkel Cell Carcinoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). 1.16 Renal Cell Carcinoma KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC. KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions [see Clinical Studies (14.16) ] . KEYTRUDA, in combination with belzutifan, is indicated for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. 1.17 Endometrial Carcinoma KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] . KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] . 1.18 Tumor Mutational Burden-High Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.18) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. 1.19 Cutaneous Squamous Cell Carcinoma KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation. 1.20 Triple-Negative Breast Cancer KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYTRUDA, in combination with sacituzumab govitecan-hziy, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.21 Ovarian Cancer KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , and who have received one or two prior systemic treatment regimens.
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- Merck Sharp & Dohme LLC
- matched search terms
- cancer
- carcinoma
- lymphoma
- melanoma
- tumor
- tumors
- malignant
- package ndcs
- 0006-3029-01
- 0006-3029-02
- 0006-3026-01
- 0006-3026-02
- 0006-3026-04
- product ndcs
- 0006-3026
- 0006-3029
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- Indications and Usage ( 1 ) 07/2026 Dosage and Administration ( 2 ) 07/2026 Warnings and Precautions ( 5 ) 05/2026
- record type
- complete_spl_indications_section_candidate
- routes
- INTRAVENOUS
- rxcuis
- 1657746
- 1657749
- 1657750
- 1657751
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00100.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 100
- total
- 830
- sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl effective time
- 20260710
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- substance names
- PEMBROLIZUMAB
- uniis
- DPT0O3T46P
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
- fda_label_posted_after_spl_effective_date_requires_version_review
Drugs@FDA application source records
- application number
- BLA125514
- payload
- all indexed label documents
- Appl No
- 125514
- Application Docs Date
- 2019-06-05 00:00:00
- Application Docs ID
- 18929
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s003lbl.pdf
- Submission No
- 3
- Submission Type
- SUPPL
- Appl No
- 125514
- Application Docs Date
- 2015-12-18 00:00:00
- Application Docs ID
- 18930
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s004s006lbl.pdf
- Submission No
- 4
- Submission Type
- SUPPL
- Appl No
- 125514
- Application Docs Date
- 2015-10-02 00:00:00
- Application Docs ID
- 18931
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s005lbl.pdf
- Submission No
- 5
- Submission Type
- SUPPL
- Appl No
- 125514
- Application Docs Date
- 2014-09-04 00:00:00
- Application Docs ID
- 39983
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf
- Submission No
- 1
- Submission Type
- ORIG
- Appl No
- 125514
- Application Docs Date
- 2015-12-18 00:00:00
- Application Docs ID
- 39984
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s004s006lbl.pdf
- Submission No
- 6
- Submission Type
- SUPPL
- Appl No
- 125514
- Application Docs Date
- 2016-08-05 00:00:00
- Application Docs ID
- 44996
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s009lbl.pdf
- Submission No
- 9
- Submission Type
- SUPPL
- Appl No
- 125514
- Application Docs Date
- 2016-10-25 00:00:00
- Application Docs ID
- 45592
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdf
- Submission No
- 12
- Submission Type
- SUPPL
- Appl No
- 125514
- Application Docs Date
- 2016-10-31 00:00:00
- Application Docs ID
- 45722
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s008s012lbl.pdf
- Submission No
- 8
- Submission Type
- SUPPL
- Appl No
- 125514
- Application Docs Date
- 2017-03-14 00:00:00
- Application Docs ID
- 47558
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s015lbl.pdf
- Submission No
- 15
- Submission Type
- SUPPL
- Appl No
- 125514
- Application Docs Date
- 2017-05-11 00:00:00
- Application Docs ID
- 48350
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s016lbl.pdf
- Submission No
- 16
- Submission Type
- SUPPL
- Appl No
- 125514
- Application Docs Date
- 2017-05-18 00:00:00
- Application Docs ID
- 48438
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s017s018lbl.pdf
- Submission No
- 17
- Submission Type
- SUPPL
- Appl No
- 125514
- Application Docs Date
- 2017-05-18 00:00:00
- Application Docs ID
- 48439
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s017s018lbl.pdf
- Submission No
- 18
- Submission Type
- SUPPL
- all submission records
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 138
- Submission Status
- AP
- Submission Status Date
- 2023-10-12 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- PRIORITY
- Submission Class Code ID
- 2
- Submission No
- 136
- Submission Status
- AP
- Submission Status Date
- 2023-04-03 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 135
- Submission Status
- AP
- Submission Status Date
- 2023-08-14 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 134
- Submission Status
- AP
- Submission Status Date
- 2023-08-14 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 133
- Submission Status
- AP
- Submission Status Date
- 2022-08-05 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 132
- Submission Status
- AP
- Submission Status Date
- 2023-03-28 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 131
- Submission Status
- AP
- Submission Status Date
- 2022-06-21 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 128
- Submission Status
- AP
- Submission Status Date
- 2023-01-26 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 127
- Submission Status
- AP
- Submission Status Date
- 2022-12-16 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 125
- Submission Status
- AP
- Submission Status Date
- 2022-02-04 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 124
- Submission Status
- AP
- Submission Status Date
- 2024-01-25 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125514
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 123
- Submission Status
- AP
- Submission Status Date
- 2022-05-20 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- application number
- BLA125514
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514
- has approved submission record
- true
- latest approved submission date
- 2026-07-10
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 125514
- Application Docs Date
- 2026-07-15 00:00:00
- Application Docs ID
- 86556
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s194lbl.pdf
- Submission No
- 194
- Submission Type
- SUPPL
- official application record
- Appl No
- 125514
- Appl Public Notes
- Appl Type
- BLA
- Sponsor Name
- MERCK SHARP DOHME
- openfda application present
- true
- products
- Active Ingredient
- PEMBROLIZUMAB
- Appl No
- 125514
- Drug Name
- KEYTRUDA
- Form
- SOLUTION;INTRAVENOUS
- Product No
- 001
- Reference Drug
- 0
- Reference Standard
- Strength
- 100MG/4ML (25MG/ML)
- marketing status
- Prescription
Source passages and status connections
Passage 1 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 382
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) i
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-7b15aa806bd9061ed2c1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-6a27a2e082e794ef2b92
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 100
- end exclusive
- true
- exact text
- is a programmed death receptor-1 (PD-1)-blocking antibody indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 33
- qualifier mentions
- context exact
- Melanoma for the treatment of patients with unresectable or metastatic melanoma.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 181
- end exclusive
- true
- exact text
- metastatic melanoma
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 162
- context exact
- body indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 181
- end exclusive
- true
- exact text
- unresectable or metastatic melanoma
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 146
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 182
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 2 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 390
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combin
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-7d96d06ad0b13d3985cc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-4097a1c282096baaa34f
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 190
- end exclusive
- true
- exact text
- ( 1.1 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 183
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 3 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 537
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-e620b75868053fe02ae4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-23ea9409c3e169317afc
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 100
- end exclusive
- true
- exact text
- is a programmed death receptor-1 (PD-1)-blocking antibody indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 33
- qualifier mentions
- context exact
- for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB,
- kind
- age
- polarity
- not_inferred
- span
- end
- 226
- end exclusive
- true
- exact text
- adult
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 221
- context exact
- for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III m
- kind
- age
- polarity
- not_inferred
- span
- end
- 240
- end exclusive
- true
- exact text
- pediatric
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 231
- context exact
- for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following co
- kind
- age
- polarity
- not_inferred
- span
- end
- 260
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 242
- context exact
- for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III mel
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 242
- end exclusive
- true
- exact text
- adjuvant treatment of adult and pediatric (
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 199
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 337
- end exclusive
- true
- exact text
- for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 191
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 4 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 756
- end exclusive
- true
- exact text
- ts with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 138
- current approval status
- not_reconciled
- duplicate text group
- dup-2db7555f10691876b74d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-1e7dde1ebb614e27532d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 100
- end exclusive
- true
- exact text
- is a programmed death receptor-1 (PD-1)-blocking antibody indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 33
- qualifier mentions
- context exact
- inum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 508
- end exclusive
- true
- exact text
- metastatic nonsquamous NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 480
- context exact
- ment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 555
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 518
- context exact
- inum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 508
- end exclusive
- true
- exact text
- metastatic nonsquamous NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 480
- context exact
- n combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 555
- end exclusive
- true
- exact text
- first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 442
- context exact
- ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 555
- end exclusive
- true
- exact text
- in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 381
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 556
- end exclusive
- true
- exact text
- ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 338
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 5 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 764
- end exclusive
- true
- exact text
- ell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line tre
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 357
- current approval status
- not_reconciled
- duplicate text group
- dup-cae292898e7240dcc6f1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-6c413db61d24a2e5395c
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 564
- end exclusive
- true
- exact text
- ( 1.2 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 557
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 6 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 915
- end exclusive
- true
- exact text
- Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 365
- current approval status
- not_reconciled
- duplicate text group
- dup-18c575534e5a16bf3a0a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-c45f10094f4c9a92258a
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 100
- end exclusive
- true
- exact text
- is a programmed death receptor-1 (PD-1)-blocking antibody indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 33
- qualifier mentions
- context exact
- xel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 714
- end exclusive
- true
- exact text
- metastatic squamous NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 689
- context exact
- xel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 714
- end exclusive
- true
- exact text
- metastatic squamous NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 689
- context exact
- latin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 714
- end exclusive
- true
- exact text
- first-line treatment of patients with metastatic squamous NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 651
- context exact
- in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 714
- end exclusive
- true
- exact text
- in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 565
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 715
- end exclusive
- true
- exact text
- in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 565
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 7 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 923
- end exclusive
- true
- exact text
- o EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor ab
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 516
- current approval status
- not_reconciled
- duplicate text group
- dup-cae292898e7240dcc6f1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-755e3787a9d9c0a611a6
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 723
- end exclusive
- true
- exact text
- ( 1.2 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 716
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 8 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1253
- end exclusive
- true
- exact text
- r ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on or after
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 524
- current approval status
- not_reconciled
- duplicate text group
- dup-c230663d5e2fdcee8f52
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-4539e078388a3cac24af
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 100
- end exclusive
- true
- exact text
- is a programmed death receptor-1 (PD-1)-blocking antibody indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 33
- qualifier mentions
- context exact
- the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK gen
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 850
- end exclusive
- true
- exact text
- PD-L1 [Tumor Proportion Score (TPS) ≥1%] as d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 805
- context exact
- (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for su
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 932
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 895
- context exact
- tes for surgical resection or definitive chemoradiation, or metastatic.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1052
- end exclusive
- true
- exact text
- metastatic
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1042
- context exact
- tes for surgical resection or definitive chemoradiation, or metastatic.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1052
- end exclusive
- true
- exact text
- metastatic
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1042
- context exact
- as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candi
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 920
- end exclusive
- true
- exact text
- first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 750
- context exact
- as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where pat
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 901
- end exclusive
- true
- exact text
- as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR o
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 724
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 1053
- end exclusive
- true
- exact text
- as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 724
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 9 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1486
- end exclusive
- true
- exact text
- mined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patie
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 854
- current approval status
- not_reconciled
- duplicate text group
- dup-641d194608f28a75e22c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-6dba420e66b7df41d13b
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with dis
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1164
- end exclusive
- true
- exact text
- metastatic NSCLC whose tumors express PD-L1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1121
- context exact
- 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disea
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1166
- end exclusive
- true
- exact text
- metastatic NSCLC whose tumors express PD-L1 (
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1121
- context exact
- ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on or after platinum-containing chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1245
- end exclusive
- true
- exact text
- as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on o
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1068
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 1286
- end exclusive
- true
- exact text
- ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on or after platinum-containing chemotherapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1054
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 10 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1645
- end exclusive
- true
- exact text
- or the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1087
- current approval status
- not_reconciled
- duplicate text group
- dup-06445d0b116646587e17
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-9493ebeab90b98aa5902
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1345
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations should
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1301
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 1445
- end exclusive
- true
- exact text
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1287
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 11 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1896
- end exclusive
- true
- exact text
- after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesoth
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1246
- current approval status
- not_reconciled
- duplicate text group
- dup-e46fb2a9efac371ad334
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-4a166529de3c45aab007
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1540
- end exclusive
- true
- exact text
- resectable (tumors ≥4 cm or node positive) NS
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1495
- context exact
- CLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1621
- end exclusive
- true
- exact text
- neoadjuvant treatment
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1600
- context exact
- adjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1695
- end exclusive
- true
- exact text
- adjuvant treatment after surgery
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1663
- context exact
- ients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1695
- end exclusive
- true
- exact text
- in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1544
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 1696
- end exclusive
- true
- exact text
- ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1446
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1904
- end exclusive
- true
- exact text
- sectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1497
- current approval status
- not_reconciled
- duplicate text group
- dup-cae292898e7240dcc6f1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-33233721bc8285e82a4d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 1704
- end exclusive
- true
- exact text
- ( 1.2 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1697
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 13 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2063
- end exclusive
- true
- exact text
- (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1505
- current approval status
- not_reconciled
- duplicate text group
- dup-407a9c4e8b400b785a2f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-a4d24a6766f4ae469a79
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ent following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1817
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1803
- context exact
- as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1771
- end exclusive
- true
- exact text
- adjuvant treatment following resection and
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1728
- context exact
- as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1862
- end exclusive
- true
- exact text
- as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1705
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 1863
- end exclusive
- true
- exact text
- as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1705
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 14 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2254
- end exclusive
- true
- exact text
- djuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determin
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1664
- current approval status
- not_reconciled
- duplicate text group
- dup-eb4f8ba5f9df02769a94
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-51f6e87ba8aa23cd49b8
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- rexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2008
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1994
- context exact
- e treatment of adult patients with unresectable advanced or metastatic MPM.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2053
- end exclusive
- true
- exact text
- metastatic MPM
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2039
- context exact
- hemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2053
- end exclusive
- true
- exact text
- unresectable advanced or metastatic MPM
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2014
- context exact
- n combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 2053
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable advanced or metastatic MPM
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1970
- context exact
- ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2053
- end exclusive
- true
- exact text
- in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1909
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 2054
- end exclusive
- true
- exact text
- ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1864
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 15 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2651
- end exclusive
- true
- exact text
- A NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of p
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 1855
- current approval status
- not_reconciled
- duplicate text group
- dup-635ac889b81974eb973b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-dcb5a87d6e01d76468dc
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express
- kind
- age
- polarity
- not_inferred
- span
- end
- 2141
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2127
- context exact
- with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test, as a single agent as ne
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2247
- end exclusive
- true
- exact text
- PD-L1 [Combined Positive Score (CPS) ≥1] as d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2202
- context exact
- ell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determ
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2192
- end exclusive
- true
- exact text
- resectable locally advanced HNSCC whose tumor
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2147
- context exact
- determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiot
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2326
- end exclusive
- true
- exact text
- neoadjuvant treatment
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2305
- context exact
- t, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2384
- end exclusive
- true
- exact text
- adjuvant treatment in combination with radi
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2341
- context exact
- ve Score (CPS) ≥1] as determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2450
- end exclusive
- true
- exact text
- as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2284
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 2451
- end exclusive
- true
- exact text
- ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2055
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 16 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2659
- end exclusive
- true
- exact text
- ined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2252
- current approval status
- not_reconciled
- duplicate text group
- dup-643d7acb74987b5a60b2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-abc297db9982e93e8db4
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 2459
- end exclusive
- true
- exact text
- ( 1.4 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2452
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 17 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2791
- end exclusive
- true
- exact text
- an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2260
- current approval status
- not_reconciled
- duplicate text group
- dup-a7fbd5c636e9d561bac2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-1063c042d5c92e3a7553
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- atinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2573
- end exclusive
- true
- exact text
- metastatic or with unresectable
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2542
- context exact
- atinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2573
- end exclusive
- true
- exact text
- metastatic or with unresectable
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2542
- context exact
- treatment of patients with metastatic or with unresectable, recurrent HNSCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2590
- end exclusive
- true
- exact text
- recurrent HNSCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2575
- context exact
- in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 2590
- end exclusive
- true
- exact text
- first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2504
- context exact
- in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2590
- end exclusive
- true
- exact text
- in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2460
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 2591
- end exclusive
- true
- exact text
- in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2460
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 18 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2799
- end exclusive
- true
- exact text
- (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2392
- current approval status
- not_reconciled
- duplicate text group
- dup-643d7acb74987b5a60b2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-600a6ee241f36b3a02a3
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 2599
- end exclusive
- true
- exact text
- ( 1.4 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2592
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 19 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3015
- end exclusive
- true
- exact text
- th or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymph
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2400
- current approval status
- not_reconciled
- duplicate text group
- dup-832576c39b27676e59b2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-bb7aefacd08074f13396
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Posit
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2695
- end exclusive
- true
- exact text
- metastatic or with unresectable
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2664
- context exact
- or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2779
- end exclusive
- true
- exact text
- PD-L1 [Combined Positive Score (CPS) ≥1] as d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2734
- context exact
- single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Posit
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2695
- end exclusive
- true
- exact text
- metastatic or with unresectable
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2664
- context exact
- treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-au
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2741
- end exclusive
- true
- exact text
- recurrent HNSCC whose tumors express PD-L1 [
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2697
- context exact
- as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 2796
- end exclusive
- true
- exact text
- first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an F
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2626
- context exact
- as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2777
- end exclusive
- true
- exact text
- as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2600
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 2815
- end exclusive
- true
- exact text
- as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2600
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 20 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3183
- end exclusive
- true
- exact text
- t for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has rela
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2616
- current approval status
- not_reconciled
- duplicate text group
- dup-d0b22f95c0e6418875bb
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-be900f87ff091e52fa2a
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ingle agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2939
- end exclusive
- true
- exact text
- metastatic HNSCC with disease progression o
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2896
- context exact
- 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2927
- end exclusive
- true
- exact text
- recurrent or metastatic HNSCC with disease p
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2883
- context exact
- ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2982
- end exclusive
- true
- exact text
- as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2830
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 2983
- end exclusive
- true
- exact text
- ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2816
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 21 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3293
- end exclusive
- true
- exact text
- ined by an FDA-authorized test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treat
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2784
- current approval status
- not_reconciled
- duplicate text group
- dup-7b5b7f378deef935215a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-1cab51f3c3f6d27be27b
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL.
- kind
- age
- polarity
- not_inferred
- span
- end
- 3060
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3046
- context exact
- kin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3092
- end exclusive
- true
- exact text
- relapsed or refractory cHL
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3066
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 3093
- end exclusive
- true
- exact text
- ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2984
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 22 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3301
- end exclusive
- true
- exact text
- r metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2894
- current approval status
- not_reconciled
- duplicate text group
- dup-2b910a539db37eda31b8
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-be7750631d2457cb827c
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 3101
- end exclusive
- true
- exact text
- ( 1.5 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3094
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 23 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3421
- end exclusive
- true
- exact text
- atic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 2902
- current approval status
- not_reconciled
- duplicate text group
- dup-1d989b5613ba8b7ea7a8
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-ea2b1cfd51726aa9ca31
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or mo
- kind
- age
- polarity
- not_inferred
- span
- end
- 3141
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3123
- context exact
- for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3161
- end exclusive
- true
- exact text
- refractory cHL
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3147
- context exact
- of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3220
- end exclusive
- true
- exact text
- relapsed after 2 or more lines of therapy
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3179
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 3221
- end exclusive
- true
- exact text
- for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3102
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 24 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3613
- end exclusive
- true
- exact text
- L) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin-ejfv,
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3022
- current approval status
- not_reconciled
- duplicate text group
- dup-eccb80aeb3dfcca100bd
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-c60fc84a1a71eb61d91e
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- iastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have r
- kind
- age
- polarity
- not_inferred
- span
- end
- 3306
- end exclusive
- true
- exact text
- adult
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3301
- context exact
- arge B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more
- kind
- age
- polarity
- not_inferred
- span
- end
- 3329
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3311
- context exact
- BCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therap
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3351
- end exclusive
- true
- exact text
- refractory PMBCL
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3335
- context exact
- t and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3408
- end exclusive
- true
- exact text
- relapsed after 2 or more prior lines of the
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3365
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 3413
- end exclusive
- true
- exact text
- ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3222
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 25 · limitation of use
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 3749
- end exclusive
- true
- exact text
- herapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment o
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3214
- current approval status
- not_reconciled
- duplicate text group
- dup-2127162361c4f81adbc4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-84382ff4e227f51ae527
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 3549
- end exclusive
- true
- exact text
- ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3414
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 26 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3903
- end exclusive
- true
- exact text
- L, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease pr
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3350
- current approval status
- not_reconciled
- duplicate text group
- dup-f36b0048b2aaef188db0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-5e4fd4a3a94b790942ab
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- bination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- kind
- age
- polarity
- not_inferred
- span
- end
- 3648
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3634
- context exact
- or the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3702
- end exclusive
- true
- exact text
- metastatic urothelial cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3674
- context exact
- umab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3702
- end exclusive
- true
- exact text
- locally advanced or metastatic urothelial cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3654
- context exact
- Urothelial Cancer in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 3702
- end exclusive
- true
- exact text
- in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3568
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 3703
- end exclusive
- true
- exact text
- Urothelial Cancer in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3550
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 27 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3911
- end exclusive
- true
- exact text
- BCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progressio
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3504
- current approval status
- not_reconciled
- duplicate text group
- dup-9bc82f6b7083214ae7dc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-da459c1b8101bcccbc31
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 3711
- end exclusive
- true
- exact text
- ( 1.7 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3704
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 28 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4261
- end exclusive
- true
- exact text
- require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin-ejfv, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC). (
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3512
- current approval status
- not_reconciled
- duplicate text group
- dup-fa6e37400c7a8df902ba
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-5bbac07fcd64d7c36ccb
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- gent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3828
- end exclusive
- true
- exact text
- metastatic urothelial carcinoma who: are no
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3785
- context exact
- as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemother
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3816
- end exclusive
- true
- exact text
- locally advanced or metastatic urothelial carcinoma
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3765
- context exact
- ing platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4035
- end exclusive
- true
- exact text
- neoadjuvant or adjuvant treatment with platinu
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3989
- context exact
- as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-contain
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 3889
- end exclusive
- true
- exact text
- as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who h
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3712
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 4061
- end exclusive
- true
- exact text
- as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3712
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 29 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4269
- end exclusive
- true
- exact text
- ning chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.7 ) a
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3862
- current approval status
- not_reconciled
- duplicate text group
- dup-9bc82f6b7083214ae7dc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-aa0587adadb100b40043
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 4069
- end exclusive
- true
- exact text
- ( 1.7 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4062
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 30 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4459
- end exclusive
- true
- exact text
- motherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or wi
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 3870
- current approval status
- not_reconciled
- duplicate text group
- dup-67211352c80cd7656cf3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-00186473950da1032d71
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- nd then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC).
- kind
- age
- polarity
- not_inferred
- span
- end
- 4215
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4201
- context exact
- in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with mus
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4164
- end exclusive
- true
- exact text
- neoadjuvant treatment and then continued after
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4118
- context exact
- eoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4222
- end exclusive
- true
- exact text
- adjuvant treatment of adult patients with m
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4179
- context exact
- in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 4249
- end exclusive
- true
- exact text
- in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder canc
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4070
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 4259
- end exclusive
- true
- exact text
- in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC).
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4070
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 31 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4467
- end exclusive
- true
- exact text
- . ( 1.7 ) in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without pa
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4060
- current approval status
- not_reconciled
- duplicate text group
- dup-9bc82f6b7083214ae7dc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-3227dfb9b0341fcc9f9d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 4267
- end exclusive
- true
- exact text
- ( 1.7 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4260
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 32 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4747
- end exclusive
- true
- exact text
- ) in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) o
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4068
- current approval status
- not_reconciled
- duplicate text group
- dup-da08f030759f010770ce
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-2110bf1f1b3c0744f7e6
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 4445
- end exclusive
- true
- exact text
- as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (C
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4268
- context exact
- nvasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 4546
- end exclusive
- true
- exact text
- with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4449
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 4547
- end exclusive
- true
- exact text
- as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4268
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 33 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5143
- end exclusive
- true
- exact text
- CG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4348
- current approval status
- not_reconciled
- duplicate text group
- dup-7178aa0b42f09c07d2c4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-1c248cc682f819fc4a05
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- gh or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic micr
- kind
- age
- polarity
- not_inferred
- span
- end
- 4650
- end exclusive
- true
- exact text
- adult
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4645
- context exact
- atch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-
- kind
- age
- polarity
- not_inferred
- span
- end
- 4673
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4655
- context exact
- atment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4738
- end exclusive
- true
- exact text
- metastatic microsatellite instability-high
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4695
- context exact
- unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that ha
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4784
- end exclusive
- true
- exact text
- MSI-H) or mismatch repair deficient (dMMR) so
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4739
- context exact
- ncer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) soli
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4726
- end exclusive
- true
- exact text
- unresectable or metastatic microsatellite insta
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4679
- context exact
- d by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4942
- end exclusive
- true
- exact text
- prior treatment and who have no satisfactory alternative treatment options
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4868
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 4943
- end exclusive
- true
- exact text
- ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4548
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 34 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5383
- end exclusive
- true
- exact text
- ) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or meta
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4744
- current approval status
- not_reconciled
- duplicate text group
- dup-b0fea78a82cc508f33e3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-69485f801d79abfb64d7
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- er (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5137
- end exclusive
- true
- exact text
- metastatic MSI-H or dMMR colorectal cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5094
- context exact
- Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5125
- end exclusive
- true
- exact text
- unresectable or metastatic MSI-H or dMMR colore
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5078
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 5183
- end exclusive
- true
- exact text
- ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4944
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 35 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5738
- end exclusive
- true
- exact text
- -High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or g
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 4984
- current approval status
- not_reconciled
- duplicate text group
- dup-6697e06cae73934c8881
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-fc2ac0899494521466bb
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- um-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-posit
- kind
- age
- polarity
- not_inferred
- span
- end
- 5340
- end exclusive
- true
- exact text
- adults
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5334
- context exact
- e treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5422
- end exclusive
- true
- exact text
- metastatic HER2-positive gastric or gastroe
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5379
- context exact
- ophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5528
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥1) as determined by an FDA-author
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5483
- context exact
- g chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarci
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5397
- end exclusive
- true
- exact text
- locally advanced unresectable or metastatic HER2-po
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5346
- context exact
- ropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 5480
- end exclusive
- true
- exact text
- first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors expre
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5310
- context exact
- ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adeno
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 5392
- end exclusive
- true
- exact text
- in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HE
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5213
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 5538
- end exclusive
- true
- exact text
- ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5184
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 36 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5747
- end exclusive
- true
- exact text
- s with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesop
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5339
- current approval status
- not_reconciled
- duplicate text group
- dup-b1f57464a5d8491238d1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-d495e0b48c704b1ed852
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 5547
- end exclusive
- true
- exact text
- ( 1.10 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5539
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 37 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 6060
- end exclusive
- true
- exact text
- cally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) car
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5348
- current approval status
- not_reconciled
- duplicate text group
- dup-35cedd752224cffde7f5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-59344f6de4a700f4db51
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- um-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negat
- kind
- age
- polarity
- not_inferred
- span
- end
- 5662
- end exclusive
- true
- exact text
- adults
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5656
- context exact
- e treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5744
- end exclusive
- true
- exact text
- metastatic HER2-negative gastric or gastroe
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5701
- context exact
- ophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5850
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥1) as determined by an FDA-author
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5805
- context exact
- g chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarci
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5719
- end exclusive
- true
- exact text
- locally advanced unresectable or metastatic HER2-ne
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5668
- context exact
- ropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 5802
- end exclusive
- true
- exact text
- first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors expre
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5632
- context exact
- in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma who
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 5727
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative g
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5548
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 5860
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5548
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 38 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 6699
- end exclusive
- true
- exact text
- s with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without exte
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5661
- current approval status
- not_reconciled
- duplicate text group
- dup-2d83746b1e846fbbe00c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-195df99a7e48286450c1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ncer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters abov
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5986
- end exclusive
- true
- exact text
- metastatic esophageal or gastroesophageal j
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5943
- context exact
- midine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, or as a single agent after one or more prior line
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6296
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥1) as determined by an FDA-author
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6251
- context exact
- atients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6488
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥10) as determined by an FDA-autho
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6443
- context exact
- 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 cent
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5974
- end exclusive
- true
- exact text
- locally advanced or metastatic esophageal or gastro
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5923
- context exact
- to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, or as a single agent after one or more prior lines of systemic therapy for pati
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 6326
- end exclusive
- true
- exact text
- in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, or as a single agen
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6147
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 6499
- end exclusive
- true
- exact text
- ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5861
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 39 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 7029
- end exclusive
- true
- exact text
- test, or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6300
- current approval status
- not_reconciled
- duplicate text group
- dup-9cb67807b61cd5f9d5fc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-d5e13754411bcbb31aae
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic s
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6656
- end exclusive
- true
- exact text
- locally advanced cervical cancer involving the lowe
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6605
- context exact
- ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 6710
- end exclusive
- true
- exact text
- in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pe
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6531
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 6829
- end exclusive
- true
- exact text
- ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA).
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6500
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 40 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 7038
- end exclusive
- true
- exact text
- cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determine
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6630
- current approval status
- not_reconciled
- duplicate text group
- dup-c2ef1c49bc72c10ac74a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-ea4e0fcf3230ed99197d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 6838
- end exclusive
- true
- exact text
- ( 1.12 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6830
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 41 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 7266
- end exclusive
- true
- exact text
- nvolving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as de
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6639
- current approval status
- not_reconciled
- duplicate text group
- dup-24c0fe7b25b00d1bd2dc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-69ff98d92def39d8a7ca
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- or the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7006
- end exclusive
- true
- exact text
- metastatic cervical cancer whose tumors exp
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6963
- context exact
- current, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7056
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥1) as determined by an FDA-author
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7011
- context exact
- bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6958
- end exclusive
- true
- exact text
- recurrent
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6949
- context exact
- or the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7008
- end exclusive
- true
- exact text
- metastatic cervical cancer whose tumors expre
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6963
- context exact
- in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7018
- end exclusive
- true
- exact text
- in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6839
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 7066
- end exclusive
- true
- exact text
- in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6839
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 42 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 7501
- end exclusive
- true
- exact text
- rapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 6867
- current approval status
- not_reconciled
- duplicate text group
- dup-5b3f89597b3eb9355523
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-bc08dcc7c0930061777e
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ingle agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7191
- end exclusive
- true
- exact text
- metastatic cervical cancer with disease pro
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7148
- context exact
- e progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7291
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥1) as determined by an FDA-author
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7246
- context exact
- 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors e
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7179
- end exclusive
- true
- exact text
- recurrent or metastatic cervical cancer with
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7135
- context exact
- ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7259
- end exclusive
- true
- exact text
- as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7082
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 7301
- end exclusive
- true
- exact text
- ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7067
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 43 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 7696
- end exclusive
- true
- exact text
- r the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7102
- current approval status
- not_reconciled
- duplicate text group
- dup-7ce900c89c4ebe4a1d68
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-f9394f05deeb026102e1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7495
- end exclusive
- true
- exact text
- PD-L1-containing regimen
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7471
- context exact
- the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 7495
- end exclusive
- true
- exact text
- who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7412
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 7496
- end exclusive
- true
- exact text
- ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7302
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 44 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 7880
- end exclusive
- true
- exact text
- est. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in comb
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7297
- current approval status
- not_reconciled
- duplicate text group
- dup-fe24f04cfc60a3e30b59
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-63977b1a39bd5a3abfb0
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7679
- end exclusive
- true
- exact text
- metastatic biliary tract cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7648
- context exact
- mcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7666
- end exclusive
- true
- exact text
- locally advanced unresectable or metastatic biliary
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7615
- context exact
- ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7679
- end exclusive
- true
- exact text
- in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7533
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 7680
- end exclusive
- true
- exact text
- ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7497
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 45 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8036
- end exclusive
- true
- exact text
- aining regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatme
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7481
- current approval status
- not_reconciled
- duplicate text group
- dup-b3b74e82ef2f7cfd97fd
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-f3bf1efb090647ddf229
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or m
- kind
- age
- polarity
- not_inferred
- span
- end
- 7744
- end exclusive
- true
- exact text
- adult
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7739
- context exact
- Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell c
- kind
- age
- polarity
- not_inferred
- span
- end
- 7767
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7749
- context exact
- t and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7835
- end exclusive
- true
- exact text
- metastatic Merkel cell carcinoma
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7803
- context exact
- MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7817
- end exclusive
- true
- exact text
- recurrent locally advanced or metastatic Mer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7773
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 7836
- end exclusive
- true
- exact text
- ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7681
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 46 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8168
- end exclusive
- true
- exact text
- ectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk o
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7637
- current approval status
- not_reconciled
- duplicate text group
- dup-978686476807a8c8b03b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-06593788b53de3c2936d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- combination with axitinib, for the first-line treatment of adult patients with advanced RCC.
- kind
- age
- polarity
- not_inferred
- span
- end
- 7949
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7935
- context exact
- itinib, for the first-line treatment of adult patients with advanced RCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7967
- end exclusive
- true
- exact text
- advanced RCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7955
- context exact
- Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 7967
- end exclusive
- true
- exact text
- first-line treatment of adult patients with advanced RCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7911
- context exact
- ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7967
- end exclusive
- true
- exact text
- in combination with axitinib, for the first-line treatment of adult patients with advanced RCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7873
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 7968
- end exclusive
- true
- exact text
- ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7837
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 47 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8177
- end exclusive
- true
- exact text
- ith recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurre
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7769
- current approval status
- not_reconciled
- duplicate text group
- dup-6e34857f45270be23dec
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-7eb56795d76eafec404f
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 7977
- end exclusive
- true
- exact text
- ( 1.16 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7969
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 48 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8275
- end exclusive
- true
- exact text
- rent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7778
- current approval status
- not_reconciled
- duplicate text group
- dup-30e412d1dbacc125101f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-7c19295bfc53386a5580
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ombination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.
- kind
- age
- polarity
- not_inferred
- span
- end
- 8056
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8042
- context exact
- atinib, for the first-line treatment of adult patients with advanced RCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8074
- end exclusive
- true
- exact text
- advanced RCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8062
- context exact
- in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 8074
- end exclusive
- true
- exact text
- first-line treatment of adult patients with advanced RCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8018
- context exact
- in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8074
- end exclusive
- true
- exact text
- in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7978
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 8075
- end exclusive
- true
- exact text
- in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7978
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 49 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8284
- end exclusive
- true
- exact text
- combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) in combin
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7876
- current approval status
- not_reconciled
- duplicate text group
- dup-6e34857f45270be23dec
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-b10efef6002449da3be0
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 8084
- end exclusive
- true
- exact text
- ( 1.16 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8076
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 50 · risk or warning
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- risk_or_warning_words_without_positive_predicate
- clinical review status
- pending
- content role
- risk_or_warning
- context span
- end
- 8465
- end exclusive
- true
- exact text
- on with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) in combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectom
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 7885
- current approval status
- not_reconciled
- duplicate text group
- dup-e5d2eda5083a3ee075bc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-4326cb3f43658ae5d2cf
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- wing nephrectomy, or following nephrectomy and resection of metastatic lesions.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 8264
- end exclusive
- true
- exact text
- metastatic lesions
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8246
- context exact
- for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephr
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8136
- end exclusive
- true
- exact text
- adjuvant treatment of patients with RCC at
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8093
- context exact
- wing nephrectomy, or following nephrectomy and resection of metastatic lesions.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8264
- end exclusive
- true
- exact text
- metastatic lesions
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8246
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 8265
- end exclusive
- true
- exact text
- for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8085
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 51 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8474
- end exclusive
- true
- exact text
- nced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) in combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or fol
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8066
- current approval status
- not_reconciled
- duplicate text group
- dup-6e34857f45270be23dec
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-ddcabb5e2ff372b5e480
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 8274
- end exclusive
- true
- exact text
- ( 1.16 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8266
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 52 · risk or warning
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- risk_or_warning_words_without_positive_predicate
- clinical review status
- pending
- content role
- risk_or_warning
- context span
- end
- 8729
- end exclusive
- true
- exact text
- ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) in combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometri
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8075
- current approval status
- not_reconciled
- duplicate text group
- dup-ef9c50a6eda640075e9a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-7c8a2ff64d17f308145f
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediat
- kind
- age
- polarity
- not_inferred
- span
- end
- 8351
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8337
- context exact
- wing nephrectomy, or following nephrectomy and resection of metastatic lesions.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 8528
- end exclusive
- true
- exact text
- metastatic lesions
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8510
- context exact
- in combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8358
- end exclusive
- true
- exact text
- adjuvant treatment of adult patients with R
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8315
- context exact
- wing nephrectomy, or following nephrectomy and resection of metastatic lesions.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8528
- end exclusive
- true
- exact text
- metastatic lesions
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8510
- context exact
- in combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of meta
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8454
- end exclusive
- true
- exact text
- in combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8275
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 8529
- end exclusive
- true
- exact text
- in combination with belzutifan, for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8275
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 53 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8942
- end exclusive
- true
- exact text
- ent of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authori
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8330
- current approval status
- not_reconciled
- duplicate text group
- dup-d8962a881252c4595eca
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-3bb6048a680fce5a6171
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ollowed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
- kind
- age
- polarity
- not_inferred
- span
- end
- 8684
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8670
- context exact
- gle agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8741
- end exclusive
- true
- exact text
- advanced or recurrent endometrial carcinoma
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8698
- context exact
- ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8740
- end exclusive
- true
- exact text
- in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinom
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8561
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 8742
- end exclusive
- true
- exact text
- ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8530
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 54 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8951
- end exclusive
- true
- exact text
- metrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test,
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8543
- current approval status
- not_reconciled
- duplicate text group
- dup-20b0e90823390e25be4a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-14eca8fc21ba20abc77c
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 8751
- end exclusive
- true
- exact text
- ( 1.17 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8743
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 55 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 9286
- end exclusive
- true
- exact text
- arcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8552
- current approval status
- not_reconciled
- duplicate text group
- dup-67be8e39eb11755bb9a4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-25bd98ee2e623a0da1a4
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair
- kind
- age
- polarity
- not_inferred
- span
- end
- 8819
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8805
- context exact
- carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic ther
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 8950
- end exclusive
- true
- exact text
- MSI-H as determined by an FDA-authorized test
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8905
- context exact
- n with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8868
- end exclusive
- true
- exact text
- advanced endometrial carcinoma that is mism
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8825
- context exact
- FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 9085
- end exclusive
- true
- exact text
- prior systemic therapy in any setting and are not candidates for curative surgery or radiation
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8991
- context exact
- in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8931
- end exclusive
- true
- exact text
- in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8752
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 9086
- end exclusive
- true
- exact text
- in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8752
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 56 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 9591
- end exclusive
- true
- exact text
- ent (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megaba
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 8887
- current approval status
- not_reconciled
- duplicate text group
- dup-6b66781cf157bc7f12cd
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-980671690e65183f8a62
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR,
- kind
- age
- polarity
- not_inferred
- span
- end
- 9156
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9142
- context exact
- adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9214
- end exclusive
- true
- exact text
- MSI-H or dMMR
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9201
- context exact
- as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9205
- end exclusive
- true
- exact text
- advanced endometrial carcinoma that is MSI-
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9162
- context exact
- FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 9390
- end exclusive
- true
- exact text
- prior systemic therapy in any setting and are not candidates for curative surgery or radiation
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9296
- context exact
- ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and a
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 9279
- end exclusive
- true
- exact text
- as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progr
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9102
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 9391
- end exclusive
- true
- exact text
- ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9087
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 57 · limitation of use
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 10135
- end exclusive
- true
- exact text
- that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9192
- current approval status
- not_reconciled
- duplicate text group
- dup-297b045265e59e2f7f0c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-80e8eab527fee0e0a8fe
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumo
- kind
- age
- polarity
- not_inferred
- span
- end
- 9477
- end exclusive
- true
- exact text
- adult
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9472
- context exact
- l Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-hig
- kind
- age
- polarity
- not_inferred
- span
- end
- 9500
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9482
- context exact
- ations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been est
- kind
- age
- polarity
- not_inferred
- span
- end
- 9866
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9848
- context exact
- ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor m
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9480
- end exclusive
- true
- exact text
- TMB-H) Cancer for the treatment of adult an
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9437
- context exact
- atment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as dete
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9565
- end exclusive
- true
- exact text
- metastatic tumor mutational burden-high (TM
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9522
- context exact
- ty and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9915
- end exclusive
- true
- exact text
- TMB-H central nervous system cancers have n
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9872
- context exact
- ncer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tum
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9553
- end exclusive
- true
- exact text
- unresectable or metastatic tumor mutational bur
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9506
- context exact
- d by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effec
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 9764
- end exclusive
- true
- exact text
- prior treatment and who have no satisfactory alternative treatment options
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9690
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 9935
- end exclusive
- true
- exact text
- ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9392
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 58 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 10310
- end exclusive
- true
- exact text
- lternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single a
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9736
- current approval status
- not_reconciled
- duplicate text group
- dup-a3a7b73a77918f8fd6ba
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-dbb6656a1389f1cb60d4
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- noma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10068
- end exclusive
- true
- exact text
- metastatic cSCC or locally advanced cSCC th
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10025
- context exact
- us Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10056
- end exclusive
- true
- exact text
- recurrent or metastatic cSCC or locally adva
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10012
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 10110
- end exclusive
- true
- exact text
- Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9936
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 59 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 10551
- end exclusive
- true
- exact text
- ve not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 9911
- current approval status
- not_reconciled
- duplicate text group
- dup-fff61b91c0217af0be92
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-02d51fb437c670628eeb
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10248
- end exclusive
- true
- exact text
- early-stage TNBC in combination with chemother
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10202
- context exact
- h-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10276
- end exclusive
- true
- exact text
- neoadjuvant treatment
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10255
- context exact
- adjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10350
- end exclusive
- true
- exact text
- adjuvant treatment after surgery
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10318
- context exact
- r the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 10350
- end exclusive
- true
- exact text
- in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10219
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 10351
- end exclusive
- true
- exact text
- ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10111
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 60 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 10560
- end exclusive
- true
- exact text
- NBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10152
- current approval status
- not_reconciled
- duplicate text group
- dup-ad293a56057ec36b7812
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-aa8c48342dd02576d2ed
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 10360
- end exclusive
- true
- exact text
- ( 1.20 )
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10352
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 61 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 10787
- end exclusive
- true
- exact text
- the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.20 , 2.1 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-auth
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10161
- current approval status
- not_reconciled
- duplicate text group
- dup-06fa25afcef5ad63eedc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-11204c83639dda1b0811
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose
- kind
- age
- polarity
- not_inferred
- span
- end
- 10455
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10441
- context exact
- ent of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10537
- end exclusive
- true
- exact text
- metastatic TNBC whose tumors express PD-L1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10494
- context exact
- n-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an F
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10508
- end exclusive
- true
- exact text
- unresectable locally advanced or metastatic TNB
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10461
- context exact
- in combination with sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 10586
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10417
- context exact
- in combination with sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 10540
- end exclusive
- true
- exact text
- in combination with sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CP
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10361
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 10587
- end exclusive
- true
- exact text
- in combination with sacituzumab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10361
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 62 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 10999
- end exclusive
- true
- exact text
- umab govitecan-hziy, for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.20 , 2.1 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.20 , 2.1 ) Ovarian Cancer in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary p
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10388
- current approval status
- not_reconciled
- duplicate text group
- dup-8f0439fc090eb67a9682
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-5d399c4e7075755eac17
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- reatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10749
- end exclusive
- true
- exact text
- metastatic TNBC whose tumors express PD-L1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10706
- context exact
- th chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-a
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10724
- end exclusive
- true
- exact text
- recurrent unresectable or metastatic TNBC wh
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10680
- context exact
- ( 1.20 , 2.1 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 10782
- end exclusive
- true
- exact text
- in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10603
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 10799
- end exclusive
- true
- exact text
- ( 1.20 , 2.1 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10588
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 63 · unclassified context
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 11363
- end exclusive
- true
- exact text
- ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test. ( 1.20 , 2.1 ) Ovarian Cancer in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens. ( 1.21 , 2.1 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verifica
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10600
- current approval status
- not_reconciled
- duplicate text group
- dup-b60a51bd3fe0dbb78ece
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-4caeaac146ff4e8a5b3d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- clitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube,
- kind
- age
- polarity
- not_inferred
- span
- end
- 10926
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10912
- context exact
- tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic t
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11085
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥1) as determined by an FDA-author
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11040
- context exact
- PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 11162
- end exclusive
- true
- exact text
- who have received one or two prior systemic treatment regimens
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11100
- context exact
- ( 1.20 , 2.1 ) Ovarian Cancer in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 11009
- end exclusive
- true
- exact text
- in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10830
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 11163
- end exclusive
- true
- exact text
- ( 1.20 , 2.1 ) Ovarian Cancer in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10800
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 64 · approval contingency
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- approval_contingency_words
- clinical review status
- pending
- content role
- approval_contingency
- context span
- end
- 11492
- end exclusive
- true
- exact text
- arian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens. ( 1.21 , 2.1 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 1.1 Melanoma KEYTRUDA ® is indicated for the treatment of pa
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 10964
- current approval status
- not_reconciled
- duplicate text group
- dup-2dd164915328f6a00edd
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-e4053d7592879c9eeb09
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 11292
- end exclusive
- true
- exact text
- ( 1.21 , 2.1 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11164
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 65 · approval contingency
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- approval_contingency_words
- clinical review status
- pending
- content role
- approval_contingency
- context span
- end
- 11631
- end exclusive
- true
- exact text
- t, and who have received one or two prior systemic treatment regimens. ( 1.21 , 2.1 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 1.1 Melanoma KEYTRUDA ® is indicated for the treatment of patients with unresectable or metastatic melanoma. KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and olde
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11093
- current approval status
- not_reconciled
- duplicate text group
- dup-81b781d538d32f2c330f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-c44c8fdb0da722a2d351
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 11431
- end exclusive
- true
- exact text
- Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11293
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 66 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 11740
- end exclusive
- true
- exact text
- val based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 1.1 Melanoma KEYTRUDA ® is indicated for the treatment of patients with unresectable or metastatic melanoma. KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. 1.2 Non-Small Cell Lung Cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11232
- current approval status
- not_reconciled
- duplicate text group
- dup-086463528bff163b24f3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-07ffe10123510628385b
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 11468
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11456
- qualifier mentions
- context exact
- ndicated for the treatment of patients with unresectable or metastatic melanoma.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11539
- end exclusive
- true
- exact text
- metastatic melanoma
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11520
- context exact
- KEYTRUDA ® is indicated for the treatment of patients with unresectable or metastatic melanoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11539
- end exclusive
- true
- exact text
- unresectable or metastatic melanoma
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11504
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 11540
- end exclusive
- true
- exact text
- 1.1 Melanoma KEYTRUDA ® is indicated for the treatment of patients with unresectable or metastatic melanoma.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11432
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 67 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 11909
- end exclusive
- true
- exact text
- ntingent upon verification and description of clinical benefit in the confirmatory trials. 1.1 Melanoma KEYTRUDA ® is indicated for the treatment of patients with unresectable or metastatic melanoma. KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. 1.2 Non-Small Cell Lung Cancer KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lun
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11341
- current approval status
- not_reconciled
- duplicate text group
- dup-1062df79a7876a102d72
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-9562f075c65b61f03886
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 11562
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11550
- qualifier mentions
- context exact
- KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB,
- kind
- age
- polarity
- not_inferred
- span
- end
- 11598
- end exclusive
- true
- exact text
- adult
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11593
- context exact
- YTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III m
- kind
- age
- polarity
- not_inferred
- span
- end
- 11612
- end exclusive
- true
- exact text
- pediatric
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11603
- context exact
- ndicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following co
- kind
- age
- polarity
- not_inferred
- span
- end
- 11632
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11614
- context exact
- KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III mel
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11614
- end exclusive
- true
- exact text
- adjuvant treatment of adult and pediatric (
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11571
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 11709
- end exclusive
- true
- exact text
- KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11541
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 68 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 12173
- end exclusive
- true
- exact text
- ctable or metastatic melanoma. KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. 1.2 Non-Small Cell Lung Cancer KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC. KEYTRUDA, as a singl
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11510
- current approval status
- not_reconciled
- duplicate text group
- dup-379c01d641c24962e45b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-ae6c41ac7f301a1bc8af
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 11821
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11809
- qualifier mentions
- context exact
- is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberration
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11911
- end exclusive
- true
- exact text
- metastatic nonsquamous non-small cell lung
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11868
- context exact
- tic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11972
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11935
- context exact
- is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11913
- end exclusive
- true
- exact text
- metastatic nonsquamous non-small cell lung ca
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11868
- context exact
- pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 11972
- end exclusive
- true
- exact text
- first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11830
- context exact
- 1.2 Non-Small Cell Lung Cancer KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 11930
- end exclusive
- true
- exact text
- in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), wit
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11751
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 11973
- end exclusive
- true
- exact text
- 1.2 Non-Small Cell Lung Cancer KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11710
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 69 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 12352
- end exclusive
- true
- exact text
- etrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC. KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test [see Dosage a
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11774
- current approval status
- not_reconciled
- duplicate text group
- dup-eb7effe8ada52f4db230
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-a7bd697f47f8f0e8177e
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 12079
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12067
- qualifier mentions
- context exact
- is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 12151
- end exclusive
- true
- exact text
- metastatic squamous NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12126
- context exact
- is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 12151
- end exclusive
- true
- exact text
- metastatic squamous NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12126
- context exact
- aclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 12151
- end exclusive
- true
- exact text
- first-line treatment of patients with metastatic squamous NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12088
- context exact
- KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 12151
- end exclusive
- true
- exact text
- in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11984
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 12152
- end exclusive
- true
- exact text
- KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11974
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 70 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 12746
- end exclusive
- true
- exact text
- c tumor aberrations. KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC. KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosage and Administrati
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 11953
- current approval status
- not_reconciled
- duplicate text group
- dup-ac8f23bb914e82996f9b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-ee562146fcdd308ef2f9
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 12194
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12182
- qualifier mentions
- context exact
- the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test [see Dosage and Administ
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 12303
- end exclusive
- true
- exact text
- PD-L1 [Tumor Proportion Score (TPS) ≥1%] as d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12258
- context exact
- rized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for su
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 12425
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12388
- context exact
- tes for surgical resection or definitive chemoradiation, or metastatic.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 12545
- end exclusive
- true
- exact text
- metastatic
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12535
- context exact
- tes for surgical resection or definitive chemoradiation, or metastatic.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 12545
- end exclusive
- true
- exact text
- metastatic
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12535
- context exact
- KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations, and i
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 12372
- end exclusive
- true
- exact text
- first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test [see Dosage and Administration (2
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12203
- context exact
- KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 12340
- end exclusive
- true
- exact text
- as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test [
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12163
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 12546
- end exclusive
- true
- exact text
- KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12153
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 71 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 13029
- end exclusive
- true
- exact text
- age and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. KEYTRUDA is indicated for the treatment
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12347
- current approval status
- not_reconciled
- duplicate text group
- dup-e01902a4c659d9ae07e5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-8376e43f3467d450dcdf
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 12588
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12576
- qualifier mentions
- context exact
- ngle agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosa
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 12667
- end exclusive
- true
- exact text
- metastatic NSCLC whose tumors express PD-L1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12624
- context exact
- ngle agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosage
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 12669
- end exclusive
- true
- exact text
- metastatic NSCLC whose tumors express PD-L1 (
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12624
- context exact
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with disease progression on or afte
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 12734
- end exclusive
- true
- exact text
- as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosage and
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12557
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 12829
- end exclusive
- true
- exact text
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with disease progression on or after platinum-containing chemotherapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12547
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 72 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 13188
- end exclusive
- true
- exact text
- atic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then conti
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12630
- current approval status
- not_reconciled
- duplicate text group
- dup-06445d0b116646587e17
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-cf1c104350cd89c17632
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 12194
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12182
- qualifier mentions
- context exact
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 12888
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations should
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12844
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 12988
- end exclusive
- true
- exact text
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12830
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 73 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 13447
- end exclusive
- true
- exact text
- after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. 1.3 Malignant Pleu
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12789
- current approval status
- not_reconciled
- duplicate text group
- dup-ec8618ca6b52a671be45
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-e07a580c30b7b3be41c8
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 13010
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12998
- qualifier mentions
- context exact
- KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 13091
- end exclusive
- true
- exact text
- resectable (tumors ≥4 cm or node positive) NS
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13046
- context exact
- CLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 13172
- end exclusive
- true
- exact text
- neoadjuvant treatment
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13151
- context exact
- adjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 13246
- end exclusive
- true
- exact text
- adjuvant treatment after surgery
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13214
- context exact
- ients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 13246
- end exclusive
- true
- exact text
- in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13095
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 13247
- end exclusive
- true
- exact text
- KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 12989
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 74 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 13628
- end exclusive
- true
- exact text
- sectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. 1.3 Malignant Pleural Mesothelioma KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metast
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13048
- current approval status
- not_reconciled
- duplicate text group
- dup-b15f1ecce66d5a8c4d76
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-af0319963e42e328b715
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 13289
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13277
- qualifier mentions
- context exact
- ent following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
- kind
- age
- polarity
- not_inferred
- span
- end
- 13382
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13368
- context exact
- KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 13336
- end exclusive
- true
- exact text
- adjuvant treatment following resection and
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13293
- context exact
- KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 13427
- end exclusive
- true
- exact text
- as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13258
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 13428
- end exclusive
- true
- exact text
- KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13248
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 75 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 13870
- end exclusive
- true
- exact text
- ent after surgery. KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. 1.3 Malignant Pleural Mesothelioma KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). 1.4 Head and Neck Squamous Cell Cancer KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] a
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13229
- current approval status
- not_reconciled
- duplicate text group
- dup-b46d454fa268c1f7727e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-e71904cf9b03ca820eb2
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 13544
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13532
- qualifier mentions
- context exact
- chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural
- kind
- age
- polarity
- not_inferred
- span
- end
- 13591
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13577
- context exact
- e treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 13665
- end exclusive
- true
- exact text
- metastatic malignant pleural mesothelioma (
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13622
- context exact
- dicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 13644
- end exclusive
- true
- exact text
- unresectable advanced or metastatic malignant p
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13597
- context exact
- pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 13669
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13553
- context exact
- 1.3 Malignant Pleural Mesothelioma KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 13653
- end exclusive
- true
- exact text
- in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural me
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13474
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 13670
- end exclusive
- true
- exact text
- 1.3 Malignant Pleural Mesothelioma KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13429
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 76 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 14317
- end exclusive
- true
- exact text
- A, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). 1.4 Head and Neck Squamous Cell Cancer KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcino
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13471
- current approval status
- not_reconciled
- duplicate text group
- dup-fcf31227be02b4f70f11
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-069ff596d2b12319b662
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 13731
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13719
- qualifier mentions
- context exact
- mous Cell Cancer KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express
- kind
- age
- polarity
- not_inferred
- span
- end
- 13767
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13753
- context exact
- with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administ
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 13873
- end exclusive
- true
- exact text
- PD-L1 [Combined Positive Score (CPS) ≥1] as d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13828
- context exact
- TRUDA is indicated for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determ
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 13818
- end exclusive
- true
- exact text
- resectable locally advanced HNSCC whose tumor
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13773
- context exact
- ee Dosage and Administration (2.1) ] , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiot
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 13992
- end exclusive
- true
- exact text
- neoadjuvant treatment
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13971
- context exact
- , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 14050
- end exclusive
- true
- exact text
- adjuvant treatment in combination with radi
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14007
- context exact
- DA-authorized test [see Dosage and Administration (2.1) ] , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 14116
- end exclusive
- true
- exact text
- as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13950
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 14117
- end exclusive
- true
- exact text
- 1.4 Head and Neck Squamous Cell Cancer KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13671
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 77 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 14528
- end exclusive
- true
- exact text
- ge and Administration (2.1) ] , as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC). KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1]
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 13918
- current approval status
- not_reconciled
- duplicate text group
- dup-67123fae2f72272002ab
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-59d7c0dbddf8ca194e9a
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 14192
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14180
- qualifier mentions
- context exact
- is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 14270
- end exclusive
- true
- exact text
- metastatic or with unresectable
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14239
- context exact
- is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 14270
- end exclusive
- true
- exact text
- metastatic or with unresectable
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14239
- context exact
- treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 14316
- end exclusive
- true
- exact text
- recurrent head and neck squamous cell carcin
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14272
- context exact
- n with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 14327
- end exclusive
- true
- exact text
- first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14201
- context exact
- KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 14307
- end exclusive
- true
- exact text
- in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous ce
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14128
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 14328
- end exclusive
- true
- exact text
- KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14118
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 78 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 14808
- end exclusive
- true
- exact text
- n combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC). KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. 1.5 Classical Hodgkin
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14129
- current approval status
- not_reconciled
- duplicate text group
- dup-b1c0adbb640f777a5c79
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-21c0cda6ef42b606d888
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 14370
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14358
- qualifier mentions
- context exact
- is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Posit
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 14448
- end exclusive
- true
- exact text
- metastatic or with unresectable
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14417
- context exact
- or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administ
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 14532
- end exclusive
- true
- exact text
- PD-L1 [Combined Positive Score (CPS) ≥1] as d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14487
- context exact
- is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Posit
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 14448
- end exclusive
- true
- exact text
- metastatic or with unresectable
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14417
- context exact
- treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-au
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 14494
- end exclusive
- true
- exact text
- recurrent HNSCC whose tumors express PD-L1 [
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14450
- context exact
- KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 14549
- end exclusive
- true
- exact text
- first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an F
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14379
- context exact
- KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dos
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 14516
- end exclusive
- true
- exact text
- as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Scor
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14339
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 14608
- end exclusive
- true
- exact text
- KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14329
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 79 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 14986
- end exclusive
- true
- exact text
- ts with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. 1.5 Classical Hodgkin Lymphoma KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL). KEYTRUDA is indicated for the treatment of pedia
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14409
- current approval status
- not_reconciled
- duplicate text group
- dup-12e1a0ec5c6fbb920426
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-c1bd61f85a8d805bccb6
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 14650
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14638
- qualifier mentions
- context exact
- s indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 14742
- end exclusive
- true
- exact text
- metastatic HNSCC with disease progression o
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14699
- context exact
- ngle agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 14730
- end exclusive
- true
- exact text
- recurrent or metastatic HNSCC with disease p
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14686
- context exact
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 14785
- end exclusive
- true
- exact text
- as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14619
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 14786
- end exclusive
- true
- exact text
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14609
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 80 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 15137
- end exclusive
- true
- exact text
- inistration (2.1) ] . KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. 1.5 Classical Hodgkin Lymphoma KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL). KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. 1.6 Primary Mediastinal Large B-Cell Lymphoma KEYTRUDA is
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14587
- current approval status
- not_reconciled
- duplicate text group
- dup-8063c20fbe9309818a9b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-50da7388488700919c86
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 14839
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14827
- qualifier mentions
- context exact
- Hodgkin Lymphoma KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL
- kind
- age
- polarity
- not_inferred
- span
- end
- 14875
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14861
- context exact
- TRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 14924
- end exclusive
- true
- exact text
- relapsed or refractory classical Hodgkin ly
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14881
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 14937
- end exclusive
- true
- exact text
- 1.5 Classical Hodgkin Lymphoma KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14787
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 81 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 15279
- end exclusive
- true
- exact text
- on on or after platinum-containing chemotherapy. 1.5 Classical Hodgkin Lymphoma KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL). KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. 1.6 Primary Mediastinal Large B-Cell Lymphoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have re
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14738
- current approval status
- not_reconciled
- duplicate text group
- dup-b641cfe1cfd7067b2d33
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-7e73091612db1cb199a1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 14959
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14947
- qualifier mentions
- context exact
- KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or mo
- kind
- age
- polarity
- not_inferred
- span
- end
- 14999
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14981
- context exact
- A is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 15019
- end exclusive
- true
- exact text
- refractory cHL
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15005
- context exact
- of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 15078
- end exclusive
- true
- exact text
- relapsed after 2 or more lines of therapy
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15037
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 15079
- end exclusive
- true
- exact text
- KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14938
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 82 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 15525
- end exclusive
- true
- exact text
- relapsed or refractory classical Hodgkin lymphoma (cHL). KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. 1.6 Primary Mediastinal Large B-Cell Lymphoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. 1.7 Urothelial Cancer KEYTRUDA, in combination with enfortumab vedotin-
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 14880
- current approval status
- not_reconciled
- duplicate text group
- dup-4f9bbb686dfed694694c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-c998e80aff4ef6cbc810
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 15147
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15135
- qualifier mentions
- context exact
- B-Cell Lymphoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal
- kind
- age
- polarity
- not_inferred
- span
- end
- 15174
- end exclusive
- true
- exact text
- adult
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15169
- context exact
- mphoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (
- kind
- age
- polarity
- not_inferred
- span
- end
- 15197
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15179
- context exact
- ated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 15248
- end exclusive
- true
- exact text
- refractory primary mediastinal large B-cell l
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15203
- context exact
- mary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 15320
- end exclusive
- true
- exact text
- relapsed after 2 or more prior lines of the
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15277
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 15325
- end exclusive
- true
- exact text
- 1.6 Primary Mediastinal Large B-Cell Lymphoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15080
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 83 · limitation of use
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 15653
- end exclusive
- true
- exact text
- KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. 1.7 Urothelial Cancer KEYTRUDA, in combination with enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. KEYTRUDA, as a sin
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15126
- current approval status
- not_reconciled
- duplicate text group
- dup-eeb6dd697ca1d69d38f9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-97664570d0025865c703
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 15453
- end exclusive
- true
- exact text
- Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15326
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 84 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 15834
- end exclusive
- true
- exact text
- a (PMBCL), or who have relapsed after 2 or more prior lines of therapy. Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. 1.7 Urothelial Cancer KEYTRUDA, in combination with enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. KEYTRUDA, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemotherapy, or who
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15254
- current approval status
- not_reconciled
- duplicate text group
- dup-f72067a80e770edca56a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-0b47f113090a39534283
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 15543
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15531
- qualifier mentions
- context exact
- enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- kind
- age
- polarity
- not_inferred
- span
- end
- 15579
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15565
- context exact
- or the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 15633
- end exclusive
- true
- exact text
- metastatic urothelial cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15605
- context exact
- ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 15633
- end exclusive
- true
- exact text
- locally advanced or metastatic urothelial cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15585
- context exact
- 1.7 Urothelial Cancer KEYTRUDA, in combination with enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 15633
- end exclusive
- true
- exact text
- in combination with enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15486
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 15634
- end exclusive
- true
- exact text
- 1.7 Urothelial Cancer KEYTRUDA, in combination with enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15454
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 85 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 16208
- end exclusive
- true
- exact text
- reductive therapy. 1.7 Urothelial Cancer KEYTRUDA, in combination with enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. KEYTRUDA, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. KEYTRUDA, in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15435
- current approval status
- not_reconciled
- duplicate text group
- dup-2c8b9ddb229ae46fe051
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-68aa15a3b57213f8eeef
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 15676
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15664
- qualifier mentions
- context exact
- ated for the treatment of patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemotherapy, or who
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 15775
- end exclusive
- true
- exact text
- metastatic urothelial carcinoma: who are no
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15732
- context exact
- ngle agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemother
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 15763
- end exclusive
- true
- exact text
- locally advanced or metastatic urothelial carcinoma
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15712
- context exact
- ing platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 15982
- end exclusive
- true
- exact text
- neoadjuvant or adjuvant treatment with platinu
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15936
- context exact
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following pl
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 15822
- end exclusive
- true
- exact text
- as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemothe
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15645
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 16008
- end exclusive
- true
- exact text
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma: who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15635
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 86 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 16440
- end exclusive
- true
- exact text
- ning chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. KEYTRUDA, in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 15809
- current approval status
- not_reconciled
- duplicate text group
- dup-c4b6ae6bcf3eae5501dc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-1be478d1c3035336cddb
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 16160
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16148
- qualifier mentions
- context exact
- my as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
- kind
- age
- polarity
- not_inferred
- span
- end
- 16196
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16182
- context exact
- KEYTRUDA, in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the trea
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 16113
- end exclusive
- true
- exact text
- neoadjuvant treatment and then continued after
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16067
- context exact
- eoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with musc
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 16146
- end exclusive
- true
- exact text
- adjuvant treatment
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16128
- context exact
- KEYTRUDA, in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 16198
- end exclusive
- true
- exact text
- in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients w
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16019
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 16240
- end exclusive
- true
- exact text
- KEYTRUDA, in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16009
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 87 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 16744
- end exclusive
- true
- exact text
- fortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. 1.8 Microsatellite Instability-High or Mismatch Repair Deficient Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instabil
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16041
- current approval status
- not_reconciled
- duplicate text group
- dup-12e3539f38edf3ed4b75
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-9a899f65487a4ee1b57b
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 16282
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16270
- qualifier mentions
- context exact
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are i
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 16428
- end exclusive
- true
- exact text
- as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcin
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16251
- context exact
- nvasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 16543
- end exclusive
- true
- exact text
- with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16446
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 16544
- end exclusive
- true
- exact text
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16241
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 88 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 17198
- end exclusive
- true
- exact text
- CG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. 1.8 Microsatellite Instability-High or Mismatch Repair Deficient Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration (2.1) ] . 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16345
- current approval status
- not_reconciled
- duplicate text group
- dup-c55209d6ec2306781bf6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-0ed256c3bad94bacb965
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 16638
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16626
- qualifier mentions
- context exact
- Deficient Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic micr
- kind
- age
- polarity
- not_inferred
- span
- end
- 16665
- end exclusive
- true
- exact text
- adult
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16660
- context exact
- Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-
- kind
- age
- polarity
- not_inferred
- span
- end
- 16688
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16670
- context exact
- atment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 16753
- end exclusive
- true
- exact text
- metastatic microsatellite instability-high
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16710
- context exact
- unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that ha
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 16799
- end exclusive
- true
- exact text
- MSI-H) or mismatch repair deficient (dMMR) so
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16754
- context exact
- ated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) soli
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 16741
- end exclusive
- true
- exact text
- unresectable or metastatic microsatellite insta
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16694
- context exact
- d by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration (2.1) ] .
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 16991
- end exclusive
- true
- exact text
- prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration (2
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16883
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 16998
- end exclusive
- true
- exact text
- 1.8 Microsatellite Instability-High or Mismatch Repair Deficient Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16545
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 89 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 17484
- end exclusive
- true
- exact text
- lid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration (2.1) ] . 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.10 Gastric Cancer KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unrese
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16799
- current approval status
- not_reconciled
- duplicate text group
- dup-a2d1444e6d7d89c29eec
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-497d42e85f5f9823f134
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 17103
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17091
- qualifier mentions
- context exact
- ndicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test [see Dosage an
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 17198
- end exclusive
- true
- exact text
- metastatic MSI-H or dMMR colorectal cancer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17155
- context exact
- er KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test [s
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 17186
- end exclusive
- true
- exact text
- unresectable or metastatic MSI-H or dMMR colore
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17139
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 17284
- end exclusive
- true
- exact text
- 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 16999
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 90 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 17893
- end exclusive
- true
- exact text
- TRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.10 Gastric Cancer KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negativ
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17085
- current approval status
- not_reconciled
- duplicate text group
- dup-2f23e10b0caed554802e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-b614880e68389670261c
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 17416
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17404
- qualifier mentions
- context exact
- chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-posit
- kind
- age
- polarity
- not_inferred
- span
- end
- 17455
- end exclusive
- true
- exact text
- adults
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17449
- context exact
- e treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 17537
- end exclusive
- true
- exact text
- metastatic HER2-positive gastric or gastroe
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17494
- context exact
- ophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 17643
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥1) as determined by an FDA-author
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17598
- context exact
- y, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarci
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 17512
- end exclusive
- true
- exact text
- locally advanced unresectable or metastatic HER2-po
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17461
- context exact
- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [s
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 17595
- end exclusive
- true
- exact text
- first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors expre
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17425
- context exact
- 1.10 Gastric Cancer KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junctio
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 17494
- end exclusive
- true
- exact text
- in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17315
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 17693
- end exclusive
- true
- exact text
- 1.10 Gastric Cancer KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17285
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 91 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 18270
- end exclusive
- true
- exact text
- metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.11 Esophageal Cancer KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17494
- current approval status
- not_reconciled
- duplicate text group
- dup-c4f4a67dc770f7ab99b7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-e75e9121ccd1dc492295
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 17792
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17780
- qualifier mentions
- context exact
- chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negat
- kind
- age
- polarity
- not_inferred
- span
- end
- 17831
- end exclusive
- true
- exact text
- adults
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17825
- context exact
- e treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 17913
- end exclusive
- true
- exact text
- metastatic HER2-negative gastric or gastroe
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17870
- context exact
- ophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 18019
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥ 1) as determined by an FDA-autho
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17974
- context exact
- y, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarci
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 17888
- end exclusive
- true
- exact text
- locally advanced unresectable or metastatic HER2-ne
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17837
- context exact
- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 17971
- end exclusive
- true
- exact text
- first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors expre
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17801
- context exact
- KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adeno
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 17883
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HE
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17704
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 18070
- end exclusive
- true
- exact text
- KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17694
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 92 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 19012
- end exclusive
- true
- exact text
- etastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.11 Esophageal Cancer KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.12 Cervical Cancer KEYTRUDA, in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, w
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 17871
- current approval status
- not_reconciled
- duplicate text group
- dup-09255b0b34f79a9c2eed
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-183a38a5173d761acb1b
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 18115
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18103
- qualifier mentions
- context exact
- ated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters abov
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 18214
- end exclusive
- true
- exact text
- metastatic esophageal or gastroesophageal j
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18171
- context exact
- ne-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , or as a
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 18528
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥ 1) as determined by an FDA-autho
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18483
- context exact
- atients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 18761
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥10) as determined by an FDA-autho
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18716
- context exact
- er KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 cent
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 18202
- end exclusive
- true
- exact text
- locally advanced or metastatic esophageal or gastro
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18151
- context exact
- to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , or as a single agent after one or
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 18554
- end exclusive
- true
- exact text
- in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18375
- context exact
- authorized test [see Dosage and Administration (2.1) ] , or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 18760
- end exclusive
- true
- exact text
- as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-auth
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18583
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 18812
- end exclusive
- true
- exact text
- 1.11 Esophageal Cancer KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18071
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 93 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 19361
- end exclusive
- true
- exact text
- more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.12 Cervical Cancer KEYTRUDA, in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18613
- current approval status
- not_reconciled
- duplicate text group
- dup-8dfe0663c64a5208bac3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-21e55f038f7ac57f4d7d
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 18901
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18889
- qualifier mentions
- context exact
- rapy (CRT), is indicated for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic s
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 18988
- end exclusive
- true
- exact text
- locally advanced cervical cancer involving the lowe
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18937
- context exact
- 1.12 Cervical Cancer KEYTRUDA, in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-func
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 19023
- end exclusive
- true
- exact text
- in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or with
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18844
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 19161
- end exclusive
- true
- exact text
- 1.12 Cervical Cancer KEYTRUDA, in combination with chemoradiotherapy (CRT), is indicated for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA).
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18813
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 94 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 19651
- end exclusive
- true
- exact text
- cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ]. KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 18962
- current approval status
- not_reconciled
- duplicate text group
- dup-c5f9043a21d1440d1611
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-e0b3147c19afb057c924
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 19247
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19235
- qualifier mentions
- context exact
- or the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 19352
- end exclusive
- true
- exact text
- metastatic cervical cancer whose tumors exp
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19309
- context exact
- current, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ].
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 19402
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥1) as determined by an FDA-author
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19357
- context exact
- is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 19304
- end exclusive
- true
- exact text
- recurrent
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19295
- context exact
- or the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [s
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 19354
- end exclusive
- true
- exact text
- metastatic cervical cancer whose tumors expre
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19309
- context exact
- KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 19351
- end exclusive
- true
- exact text
- in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors ex
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19172
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 19451
- end exclusive
- true
- exact text
- KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ].
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19162
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 95 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 19935
- end exclusive
- true
- exact text
- the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ]. KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.13 Hepatocellular Carcinoma KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19252
- current approval status
- not_reconciled
- duplicate text group
- dup-988d8872e594ac39c408
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-3339b23f9c71b06ac083
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 19493
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19481
- qualifier mentions
- context exact
- s indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 19585
- end exclusive
- true
- exact text
- metastatic cervical cancer with disease pro
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19542
- context exact
- e progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 19685
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥1) as determined by an FDA-author
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19640
- context exact
- ngle agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors e
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 19573
- end exclusive
- true
- exact text
- recurrent or metastatic cervical cancer with
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19529
- context exact
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 19639
- end exclusive
- true
- exact text
- as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19462
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 19735
- end exclusive
- true
- exact text
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19452
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 96 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 20163
- end exclusive
- true
- exact text
- nt or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.13 Hepatocellular Carcinoma KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. 1.14 Biliary Tract Cancer KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BT
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19536
- current approval status
- not_reconciled
- duplicate text group
- dup-4b5ba8a55a3c6e4397d8
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-f69d1804cc4f2697beb4
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 19787
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19775
- qualifier mentions
- context exact
- who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 19962
- end exclusive
- true
- exact text
- PD-L1-containing regimen
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19938
- context exact
- ith hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 19962
- end exclusive
- true
- exact text
- who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19879
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 19963
- end exclusive
- true
- exact text
- 1.13 Hepatocellular Carcinoma KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19736
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 97 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 20366
- end exclusive
- true
- exact text
- a KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. 1.14 Biliary Tract Cancer KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). 1.15 Merkel Cell Carcinoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). 1.16 Renal Cell Carcinoma
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19764
- current approval status
- not_reconciled
- duplicate text group
- dup-13fb179d2341f358f5ce
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-1eed40ba30ac04eb756a
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 20059
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20047
- qualifier mentions
- context exact
- treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 20165
- end exclusive
- true
- exact text
- metastatic biliary tract cancer (BTC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20128
- context exact
- cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 20146
- end exclusive
- true
- exact text
- locally advanced unresectable or metastatic biliary
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20095
- context exact
- 1.14 Biliary Tract Cancer KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 20165
- end exclusive
- true
- exact text
- in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20000
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 20166
- end exclusive
- true
- exact text
- 1.14 Biliary Tract Cancer KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19964
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 98 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 20540
- end exclusive
- true
- exact text
- 4 Biliary Tract Cancer KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). 1.15 Merkel Cell Carcinoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). 1.16 Renal Cell Carcinoma KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). KEYTRUDA, in combination with l
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 19967
- current approval status
- not_reconciled
- duplicate text group
- dup-f418b553eac0b5d4de41
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-a5b36c3967a059b3b4ba
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 20215
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20203
- qualifier mentions
- context exact
- l Cell Carcinoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or m
- kind
- age
- polarity
- not_inferred
- span
- end
- 20242
- end exclusive
- true
- exact text
- adult
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20237
- context exact
- cinoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell c
- kind
- age
- polarity
- not_inferred
- span
- end
- 20265
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20247
- context exact
- t and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 20339
- end exclusive
- true
- exact text
- metastatic Merkel cell carcinoma (MCC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20301
- context exact
- ated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 20315
- end exclusive
- true
- exact text
- recurrent locally advanced or metastatic Mer
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20271
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 20340
- end exclusive
- true
- exact text
- 1.15 Merkel Cell Carcinoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20167
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 99 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 20708
- end exclusive
- true
- exact text
- liary tract cancer (BTC). 1.15 Merkel Cell Carcinoma KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). 1.16 Renal Cell Carcinoma KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC. KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at inter
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20141
- current approval status
- not_reconciled
- duplicate text group
- dup-21923f9ebdd22da65285
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-b9b2bfb2306ada10b3e3
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 20419
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20407
- qualifier mentions
- context exact
- with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
- kind
- age
- polarity
- not_inferred
- span
- end
- 20466
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20452
- context exact
- dicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 20507
- end exclusive
- true
- exact text
- advanced renal cell carcinoma (RCC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20472
- context exact
- EYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 20507
- end exclusive
- true
- exact text
- first-line treatment of adult patients with advanced renal cell carcinoma (RCC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20428
- context exact
- 1.16 Renal Cell Carcinoma KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 20507
- end exclusive
- true
- exact text
- in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20377
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 20508
- end exclusive
- true
- exact text
- 1.16 Renal Cell Carcinoma KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20341
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 100 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 20829
- end exclusive
- true
- exact text
- ic Merkel cell carcinoma (MCC). 1.16 Renal Cell Carcinoma KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC. KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesio
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20309
- current approval status
- not_reconciled
- duplicate text group
- dup-2de67bf219b0a15923ab
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-483a13a55598b11054f4
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 20563
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20551
- qualifier mentions
- context exact
- th lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- kind
- age
- polarity
- not_inferred
- span
- end
- 20610
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20596
- context exact
- dicated for the first-line treatment of adult patients with advanced RCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 20628
- end exclusive
- true
- exact text
- advanced RCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20616
- context exact
- TRUDA, in combination with lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 20628
- end exclusive
- true
- exact text
- first-line treatment of adult patients with advanced RCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20572
- context exact
- KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 20628
- end exclusive
- true
- exact text
- in combination with lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20519
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 20629
- end exclusive
- true
- exact text
- KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20509
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 101 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- positive_statement_also_contains_qualification_review_required
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 21065
- end exclusive
- true
- exact text
- rst-line treatment of adult patients with advanced renal cell carcinoma (RCC). KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC. KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions [see Clinical Studies (14.16) ] . KEYTRUDA, in combination with belzutifan, is indicated for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence follow
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20430
- current approval status
- not_reconciled
- duplicate text group
- dup-c81a2b87f0ebf3a605f6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-b33b50ce5d67685852bd
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 20651
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20639
- qualifier mentions
- context exact
- wing nephrectomy, or following nephrectomy and resection of metastatic lesions [see Clinical Studies (14.16) ] .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 20856
- end exclusive
- true
- exact text
- metastatic lesions [see Clinical Studies (1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20813
- context exact
- KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephr
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 20703
- end exclusive
- true
- exact text
- adjuvant treatment of patients with RCC at
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20660
- context exact
- wing nephrectomy, or following nephrectomy and resection of metastatic lesions [see Clinical Studies (14.16) ] .
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 20857
- end exclusive
- true
- exact text
- metastatic lesions [see Clinical Studies (14
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20813
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 20865
- end exclusive
- true
- exact text
- KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions [see Clinical Studies (14.16) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20630
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 102 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- positive_statement_also_contains_qualification_review_required
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 21343
- end exclusive
- true
- exact text
- nt treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions [see Clinical Studies (14.16) ] . KEYTRUDA, in combination with belzutifan, is indicated for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. 1.17 Endometrial Carcinoma KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20666
- current approval status
- not_reconciled
- duplicate text group
- dup-9fb3c2e0700a89cfd92a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-288312c00fb462b1eb4b
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 20920
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20908
- qualifier mentions
- context exact
- with belzutifan, is indicated for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediat
- kind
- age
- polarity
- not_inferred
- span
- end
- 20965
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20951
- context exact
- wing nephrectomy, or following nephrectomy and resection of metastatic lesions.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 21142
- end exclusive
- true
- exact text
- metastatic lesions
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21124
- context exact
- TRUDA, in combination with belzutifan, is indicated for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 20972
- end exclusive
- true
- exact text
- adjuvant treatment of adult patients with R
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20929
- context exact
- wing nephrectomy, or following nephrectomy and resection of metastatic lesions.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 21142
- end exclusive
- true
- exact text
- metastatic lesions
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21124
- context exact
- KEYTRUDA, in combination with belzutifan, is indicated for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and rese
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 21055
- end exclusive
- true
- exact text
- in combination with belzutifan, is indicated for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurre
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20876
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 21143
- end exclusive
- true
- exact text
- KEYTRUDA, in combination with belzutifan, is indicated for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20866
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 103 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 21575
- end exclusive
- true
- exact text
- ent of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. 1.17 Endometrial Carcinoma KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 20944
- current approval status
- not_reconciled
- duplicate text group
- dup-252a9523450dc73d0f56
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-bf72568b47a8d54a16c6
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 21281
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21269
- qualifier mentions
- context exact
- YTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
- kind
- age
- polarity
- not_inferred
- span
- end
- 21317
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21303
- context exact
- indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 21374
- end exclusive
- true
- exact text
- advanced or recurrent endometrial carcinoma
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21331
- context exact
- 1.17 Endometrial Carcinoma KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 21360
- end exclusive
- true
- exact text
- in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endomet
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21181
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 21375
- end exclusive
- true
- exact text
- 1.17 Endometrial Carcinoma KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21144
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 104 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 21973
- end exclusive
- true
- exact text
- UDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] . KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease prog
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21176
- current approval status
- not_reconciled
- duplicate text group
- dup-352a04b1fce679e5d6e4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-0671d4d4572cf56bb66b
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 21430
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21418
- qualifier mentions
- context exact
- bination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair
- kind
- age
- polarity
- not_inferred
- span
- end
- 21466
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21452
- context exact
- carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic ther
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 21597
- end exclusive
- true
- exact text
- MSI-H as determined by an FDA-authorized test
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21552
- context exact
- inib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 21515
- end exclusive
- true
- exact text
- advanced endometrial carcinoma that is mism
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21472
- context exact
- FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] .
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 21766
- end exclusive
- true
- exact text
- prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21638
- context exact
- KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progressi
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 21565
- end exclusive
- true
- exact text
- in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as dete
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21386
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 21773
- end exclusive
- true
- exact text
- KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21376
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 105 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 22326
- end exclusive
- true
- exact text
- an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] . KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] . 1.18 Tumor Mutational Burden-High Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/me
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21574
- current approval status
- not_reconciled
- duplicate text group
- dup-0b167179674fd0cdc09f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-2861c32473546cd2bacf
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 21815
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21803
- qualifier mentions
- context exact
- TRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR,
- kind
- age
- polarity
- not_inferred
- span
- end
- 21851
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21837
- context exact
- adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 21909
- end exclusive
- true
- exact text
- MSI-H or dMMR
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21896
- context exact
- gent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 21900
- end exclusive
- true
- exact text
- advanced endometrial carcinoma that is MSI-
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21857
- context exact
- FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] .
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 22119
- end exclusive
- true
- exact text
- prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21991
- context exact
- KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 21961
- end exclusive
- true
- exact text
- as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21784
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 22126
- end exclusive
- true
- exact text
- KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21774
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 106 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 22744
- end exclusive
- true
- exact text
- an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration (2.1) ] . 1.18 Tumor Mutational Burden-High Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.18) ] . Continued approval for this indication may be continge
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 21927
- current approval status
- not_reconciled
- duplicate text group
- dup-20fb7e73a80832d3d109
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-4cd9d829295280901dec
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 22189
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22177
- qualifier mentions
- context exact
- rden-High Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumo
- kind
- age
- polarity
- not_inferred
- span
- end
- 22216
- end exclusive
- true
- exact text
- adult
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22211
- context exact
- Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-hig
- kind
- age
- polarity
- not_inferred
- span
- end
- 22239
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22221
- context exact
- atment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as dete
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 22304
- end exclusive
- true
- exact text
- metastatic tumor mutational burden-high (TM
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22261
- context exact
- ated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tum
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 22292
- end exclusive
- true
- exact text
- unresectable or metastatic tumor mutational bur
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22245
- context exact
- and Administration (2.1) ] , that have progressed following prior treatment and who have no satisfactory alternative treatment options.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 22543
- end exclusive
- true
- exact text
- prior treatment and who have no satisfactory alternative treatment options
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22469
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 22544
- end exclusive
- true
- exact text
- 1.18 Tumor Mutational Burden-High Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , that have progressed following prior treatment and who have no satisfactory alternative treatment options.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22127
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 107 · approval contingency
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- approval_contingency_words
- clinical review status
- pending
- content role
- approval_contingency
- context span
- end
- 22889
- end exclusive
- true
- exact text
- lid tumors, as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.18) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Limitations of Use : The safety and effectiveness of KEYTRUD
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22345
- current approval status
- not_reconciled
- duplicate text group
- dup-a1825d0e61f59492a8aa
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-a6c8a2057d9cd00440a9
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 22689
- end exclusive
- true
- exact text
- This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.18) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22545
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 108 · approval contingency
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- approval_contingency_words
- clinical review status
- pending
- content role
- approval_contingency
- context span
- end
- 23028
- end exclusive
- true
- exact text
- ho have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.18) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. 1.19 Cutaneous Squamous Cell Carcinoma KEYTRUD
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22490
- current approval status
- not_reconciled
- duplicate text group
- dup-81b781d538d32f2c330f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-5efbcad9ad61b6dc6725
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 22828
- end exclusive
- true
- exact text
- Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22690
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 109 · limitation of use
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 23181
- end exclusive
- true
- exact text
- and durability of response [see Clinical Studies (14.18) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. 1.19 Cutaneous Squamous Cell Carcinoma KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not c
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22629
- current approval status
- not_reconciled
- duplicate text group
- dup-c910e48f6b7597f6576d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-1dacf5e58a768cc4e796
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been est
- kind
- age
- polarity
- not_inferred
- span
- end
- 22912
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22894
- context exact
- ty and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 22961
- end exclusive
- true
- exact text
- TMB-H central nervous system cancers have n
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22918
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 22981
- end exclusive
- true
- exact text
- Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22829
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 110 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 23412
- end exclusive
- true
- exact text
- f clinical benefit in the confirmatory trials. Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. 1.19 Cutaneous Squamous Cell Carcinoma KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation. 1.20 Triple-Negative Breast Cancer KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22782
- current approval status
- not_reconciled
- duplicate text group
- dup-8031ee4f5751581857b7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-388fd0ee9ab34cc39565
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 23042
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23030
- qualifier mentions
- context exact
- s indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by sur
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 23134
- end exclusive
- true
- exact text
- metastatic cutaneous squamous cell carcinom
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23091
- context exact
- ma KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not cu
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 23122
- end exclusive
- true
- exact text
- recurrent or metastatic cutaneous squamous c
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23078
- context exact
- t or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 23197
- end exclusive
- true
- exact text
- locally advanced cSCC that is not curable by surger
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23146
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 23212
- end exclusive
- true
- exact text
- 1.19 Cutaneous Squamous Cell Carcinoma KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 22982
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 111 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 23696
- end exclusive
- true
- exact text
- rcinoma KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation. 1.20 Triple-Negative Breast Cancer KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYTRUDA, in combination with sacituzumab govitecan-hziy, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23013
- current approval status
- not_reconciled
- duplicate text group
- dup-0190798cf73a01389185
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-3bb5fe0bdab322061afb
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 23269
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23257
- qualifier mentions
- context exact
- A is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 23361
- end exclusive
- true
- exact text
- early-stage triple-negative breast cancer (TNB
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23315
- context exact
- ve breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 23421
- end exclusive
- true
- exact text
- neoadjuvant treatment
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23400
- context exact
- adjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 23495
- end exclusive
- true
- exact text
- adjuvant treatment after surgery
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23463
- context exact
- high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 23495
- end exclusive
- true
- exact text
- in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23364
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 23496
- end exclusive
- true
- exact text
- 1.20 Triple-Negative Breast Cancer KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23213
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 112 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 23986
- end exclusive
- true
- exact text
- ts with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYTRUDA, in combination with sacituzumab govitecan-hziy, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23297
- current approval status
- not_reconciled
- duplicate text group
- dup-f495b0abcd59b096d3f0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-1f4d410543a763364f16
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 23567
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23555
- qualifier mentions
- context exact
- ovitecan-hziy, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose
- kind
- age
- polarity
- not_inferred
- span
- end
- 23614
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23600
- context exact
- ent of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosag
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 23696
- end exclusive
- true
- exact text
- metastatic TNBC whose tumors express PD-L1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23653
- context exact
- dicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an F
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 23667
- end exclusive
- true
- exact text
- unresectable locally advanced or metastatic TNB
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23620
- context exact
- ation with sacituzumab govitecan-hziy, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 23746
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23576
- context exact
- KEYTRUDA, in combination with sacituzumab govitecan-hziy, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 23686
- end exclusive
- true
- exact text
- in combination with sacituzumab govitecan-hziy, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors expr
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23507
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 23786
- end exclusive
- true
- exact text
- KEYTRUDA, in combination with sacituzumab govitecan-hziy, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23497
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 113 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 24246
- end exclusive
- true
- exact text
- treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.21 Ovarian Cancer KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube,
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23587
- current approval status
- not_reconciled
- duplicate text group
- dup-b3bbef1b232f49863201
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-289b7897fb92ab1e941b
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 23843
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23831
- qualifier mentions
- context exact
- reatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosag
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 23956
- end exclusive
- true
- exact text
- metastatic TNBC whose tumors express PD-L1
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23913
- context exact
- py, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-a
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 23931
- end exclusive
- true
- exact text
- recurrent unresectable or metastatic TNBC wh
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23887
- context exact
- KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 23976
- end exclusive
- true
- exact text
- in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determi
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23797
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 24046
- end exclusive
- true
- exact text
- KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23787
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 114 · positive indication candidate
- application numbers
- BLA125514
- brand names
- KEYTRUDA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 24463
- end exclusive
- true
- exact text
- the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.21 Ovarian Cancer KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , and who have received one or two prior systemic treatment regimens.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 23847
- current approval status
- not_reconciled
- duplicate text group
- dup-23a354a6a6cf1acd694b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- PEMBROLIZUMAB
- id
- ind-span-a067a20864334271e82b
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- positive predicate support span
- end
- 24150
- end exclusive
- true
- exact text
- is indicated
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 24138
- qualifier mentions
- context exact
- h or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube,
- kind
- age
- polarity
- not_inferred
- span
- end
- 24186
- end exclusive
- true
- exact text
- adult patients
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 24172
- context exact
- tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , and who h
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 24345
- end exclusive
- true
- exact text
- PD-L1 (CPS ≥1) as determined by an FDA-author
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 24300
- context exact
- uthorized test [see Dosage and Administration (2.1) ] , and who have received one or two prior systemic treatment regimens.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 24462
- end exclusive
- true
- exact text
- who have received one or two prior systemic treatment regimens
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 24400
- context exact
- 1.21 Ovarian Cancer KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) a
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 24256
- end exclusive
- true
- exact text
- in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primar
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 24077
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 380
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 346
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 5042
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 5019
- source span
- end
- 24463
- end exclusive
- true
- exact text
- 1.21 Ovarian Cancer KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , and who have received one or two prior systemic treatment regimens.
- label id
- 228e1e3f-d207-481f-8e14-9fdcbd0470e9
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- e526ba14c91f10737e6d3331fe23a6219f58c0eca6380bfce9bd78b573fea912
- start
- 24047
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22228e1e3f-d207-481f-8e14-9fdcbd0470e9%22
- spl effective date
- 2026-07-10
- spl set id
- 9333c79b-d487-4538-a9f0-71b91a02b287
- spl version
- 228
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Preserved source evidence · Not medical advice
Triangle